BRISTOL-MYERS SQUIBB COMPANY Impairment of Intangible Assets (Excluding Goodwill)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Impairment of Intangible Assets (Excluding Goodwill) of $949.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets (excluding goodwill) for the quarter ending 2024-12-31 was $1.98B, a 7244.44% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets (excluding goodwill) for the quarter ending 2024-09-30 was $47.00M, a 47.19% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets (excluding goodwill) for the quarter ending 2023-12-31 was $27.00M, a 800.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets (excluding goodwill) for the quarter ending 2023-09-30 was $89.00M, a 53.45% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets (excluding goodwill) for fiscal 2025 was $949.00M, a 67.28% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets (excluding goodwill) for fiscal 2024 was $2.90B, a 2032.35% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets (excluding goodwill) for fiscal 2023 was $136.00M, a 34.65% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets (excluding goodwill) for fiscal 2022 was $101.00M, a 91.58% decline from fiscal 2021.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $949.00M 10-K · filed 2026-02-11 | ||||
| 2024-12-31 | $1.98B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.03B derived: sum of 2 quarters · filed 2026-02-11 | $2.90B 10-K · filed 2026-02-11 | ||
| 2024-09-30 | $47.00M 10-Q · filed 2024-10-31 | $917.00M 10-Q · filed 2024-10-31 | |||
| 2023-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $116.00M derived: sum of 2 quarters · filed 2026-02-11 | $116.00M derived: sum of 3 quarters · filed 2026-02-11 | $136.00M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $89.00M 10-Q · filed 2024-10-31 | $89.00M derived: sum of 2 quarters · filed 2024-10-31 | $109.00M 10-Q · filed 2024-10-31 | $112.00M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-26 | $20.00M 10-Q · filed 2024-07-26 | $23.00M derived: sum of 3 quarters · filed 2025-02-12 | $81.00M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-03-31 | $20.00M 10-Q · filed 2024-04-25 | $23.00M derived: sum of 2 quarters · filed 2025-02-12 | $81.00M derived: sum of 3 quarters · filed 2025-02-12 | $81.00M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2022-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $61.00M derived: sum of 2 quarters · filed 2025-02-12 | $61.00M derived: sum of 3 quarters · filed 2025-02-12 | $101.00M 10-K · filed 2025-02-12 | |
| 2022-09-30 | $58.00M 10-Q · filed 2023-10-26 | $58.00M derived: sum of 2 quarters · filed 2023-10-26 | $98.00M 10-Q · filed 2023-10-26 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-27 | $40.00M 10-Q · filed 2023-07-27 | |||
| 2022-03-31 | $40.00M 10-Q · filed 2023-04-27 | ||||
| 2021-12-31 | $1.20B 10-K · filed 2024-02-13 | ||||
| 2021-09-30 | $610.00M 10-Q · filed 2022-10-26 | $840.00M derived: sum of 2 quarters · filed 2022-10-26 | |||
| 2021-06-30 | $230.00M 10-Q · filed 2022-10-26 | ||||
| 2020-12-31 | $1.10B 10-K · filed 2023-02-14 | ||||
| 2019-12-31 | $66.00M 10-K · filed 2022-02-09 | ||||
| 2018-12-31 | $84.00M 10-K · filed 2021-02-10 | ||||
| 2017-12-31 | $80.00M 10-K · filed 2020-02-24 | ||||
| 2016-12-31 | $33.00M 10-K · filed 2019-02-25 | ||||
| 2015-12-31 | $181.00M 10-K · filed 2018-02-13 | ||||
| 2014-12-31 | $380.00M 10-K · filed 2017-02-21 | ||||
| 2012-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $2.10B 10-K · filed 2015-02-13 | $2.13B 10-K · filed 2013-02-15 | ||
| 2012-09-30 | $2.09B 10-Q · filed 2012-10-24 | ||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $30.00M 10-K · filed 2014-02-14 | -$30.00M 10-K · filed 2012-02-17 | ||
| 2011-09-30 | $30.00M 10-Q · filed 2012-10-24 | ||||
| 2010-12-31 | $10.00M 10-K · filed 2013-02-15 | ||||
| 2008-12-31 | $40.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |